2,271 press releases in English indexed under biotech & pharma.
First Patient Dosed with JOTROL™ Marks Major Clinical Milestone for Jupiter Neurosciences’ Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL™ in Patients with Parkinson’s Disease
CAR-T commercialization, cryopreservation, strict tracking rules, and IoT-enabled cold chains drive demand for high-barrier cell therapy packaging. CAR-T commercialization, cryopreservation, strict tracking rules, and IoT-enabled cold chains drive demand for high-barrier cell therapy packaging.
Rising cell and gene therapy adoption, stringent quality rules, and real-time batch testing needs are driving demand for specialized monitoring kits. Rising cell and gene therapy adoption, stringent quality rules, and real-time batch testing needs are driving demand for specialized monitoring kits.
Boost ROI by outsourcing sample archives to convert fixed costs into variable fees, while AI-enabled automation cuts discovery timelines, manual errors and reagent use. Boost ROI by outsourcing sample archives to convert fixed costs into variable fees, while AI-enabled automation cuts discovery timelines, manual errors and reagent use.
Boost ROI through tax credits, fee waivers, exclusivity, fast-track filings and launch sequencing; prioritize biologics, neurology and Asia-Pacific access. Boost ROI through tax credits, fee waivers, exclusivity, fast-track filings and launch sequencing; prioritize biologics, neurology and Asia-Pacific access.
Investment, strategic collaborations, scalable production and advanced cargo loading are accelerating exosome therapies across oncology, neurology and regenerative medicine. Investment, strategic collaborations, scalable production and advanced cargo loading are accelerating exosome therapies across oncology, neurology and regenerative medicine.
Luminous Mind, Inc. seeks strategic partnerships with leading nutraceutical, supplement, pharmaceutical, and venture groups to bring breakthrough products to market, potentially opening a billion-dollar-plus opportunity. BOSTON, Oct. 6, 2026 -- Luminous Mind, Inc. (LMI), a...
60 Degrees plans January 2027 results from its hospitalized babesiosis trial and will seek a pre-sNDA meeting with FDA.
ALPHARETTA, Ga., Oct. 6, 2026 -- October marks ADHD Awareness Month, shining a light on the need for timely diagnosis and personalized treatment. Vertical Pharmaceuticals is dedicated to supporting the ADHD community and the importance of precision dosing. Approximately 11.7%...
More than 550 million prescriptions were filled for medicines with High or Severe supply-chain fragility, according to APIIC’s new national benchmark More than 550 million prescriptions were filled for medicines with High or Severe supply-chain fragility, according to APIIC’s new national benchmark
Achieves key commercial project milestones utilizing its proprietary artificial intelligence (“AI”) and machine learning platform to identify and prioritize therapeutic targets Achieves key commercial project milestones utilizing its proprietary artificial intelligence (“AI”) and machine learning platform to identify and prioritize therapeutic targets
NORCROSS, Ga., Oct. 06, 2026 -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on noninvasive prediction of variceal development from the NAVIGATE and GT-026 Phase 2b trials of belapectin for the treatment of MASH cirrhosis and portal hypertension. The meeting will be held November 5-9, 2026, in Denver, Colorado.